A New Option for Treating Osteoporosis

Publisher Website
Google Scholar
Abstract
Osteoporosis is an enormous public health problem, causing more than 1.5 million fractures and costing up to $10 billion in the United States each year. The most widely used treatment is calcium supplementation. It is safe and relatively inexpensive. Calcium acts as a weak inhibitor of bone resorption, probably indirectly by decreasing the secretion of parathyroid hormone. Patients with more than mild disease usually receive estrogen or calcitonin in addition to calcium. Both have more potent antiresorptive effects and are the only agents approved by the Food and Drug Administration for the treatment of osteoporosis. Bone cells contain estrogen receptors, . . .